IRIS
ALTOMONTE, MARESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.035
EU - Europa 976
AS - Asia 211
OC - Oceania 1
SA - Sud America 1
Totale 2.224
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.031
IE - Irlanda 234
GB - Regno Unito 185
RU - Federazione Russa 130
DE - Germania 129
CN - Cina 104
IT - Italia 99
SE - Svezia 69
SG - Singapore 49
UA - Ucraina 45
FR - Francia 41
VN - Vietnam 38
ES - Italia 17
FI - Finlandia 15
KR - Corea 9
IN - India 4
AZ - Azerbaigian 3
CH - Svizzera 3
HR - Croazia 2
IM - Isola di Man 2
AU - Australia 1
BG - Bulgaria 1
BO - Bolivia 1
CA - Canada 1
DO - Repubblica Dominicana 1
EE - Estonia 1
IL - Israele 1
JP - Giappone 1
LV - Lettonia 1
MX - Messico 1
MY - Malesia 1
NL - Olanda 1
PA - Panama 1
PK - Pakistan 1
PL - Polonia 1
Totale 2.224
Salva come PNG Salva come JPEG
Città #
Dublin 233
Fairfield 166
Southend 166
Ashburn 98
Houston 78
Woodbridge 78
Cambridge 69
Wilmington 69
Seattle 51
Chandler 49
Siena 47
Santa Clara 45
Jacksonville 43
Singapore 40
Dong Ket 38
Princeton 37
Ann Arbor 32
Dearborn 31
Beijing 23
New York 19
Málaga 17
San Mateo 17
Shanghai 16
Helsinki 11
Nanjing 11
San Diego 11
London 8
Moscow 7
Nanchang 6
Yongsan-gu 6
San Giovanni Valdarno 5
Venezia 5
Boardman 4
Hefei 4
Jinan 4
Baku 3
Düsseldorf 3
Empoli 3
Florence 3
Karlsruhe 3
Kunming 3
Newark 3
Palermo 3
Rome 3
Schwielowsee 3
Tianjin 3
Zurich 3
Altamura 2
Asciano 2
Carmignano 2
Changsha 2
Chiusdino 2
Delhi 2
Falls Church 2
Guangzhou 2
Hangzhou 2
Islington 2
Kilburn 2
Livorno 2
Ningbo 2
Phoenix 2
Saha-gu 2
San Francisco 2
Zagreb 2
Acton 1
Amsterdam 1
Arezzo 1
Canberra 1
Changchun 1
Fremont 1
Fuzhou 1
Guiyang 1
Hebei 1
Hounslow 1
Hyderabad 1
Islamabad 1
Jiaxing 1
La Paz 1
Lanzhou 1
Lappeenranta 1
Los Angeles 1
Lucca 1
Mexico City 1
Nanning 1
Norwalk 1
Redmond 1
Reston 1
Richmond 1
Riga 1
Roseto Degli Abruzzi 1
Santo Domingo Este 1
Shaoxing 1
Shenyang 1
Shinjuku 1
Sofia 1
Stockholm 1
Tallinn 1
Tel Aviv 1
Toronto 1
Vicenza 1
Totale 1.650
Salva come PNG Salva come JPEG
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 220
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 183
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 177
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 147
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 129
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 126
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 118
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 111
Biology and clinical applications of CD40 in cancer treatment 111
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 109
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 108
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 106
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 89
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 84
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 76
null 75
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 73
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 63
null 58
Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort 56
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 40
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 30
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 2
Totale 2.291
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.346
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.346
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020584 0 0 0 0 95 81 123 97 78 68 18 24
2020/2021432 27 30 29 27 46 46 29 66 22 35 12 63
2021/2022212 18 21 20 3 4 11 7 11 13 26 25 53
2022/2023313 20 25 57 25 16 57 13 26 27 18 21 8
2023/2024324 16 4 30 12 4 87 124 6 5 2 17 17
2024/2025195 14 24 75 19 63 0 0 0 0 0 0 0
Totale 2.291